The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Professor Catherine Thieblemont
Scientific Advisory Board Member
Professor Catherine Thieblemont is the Head of the Hemato-Oncology Department at Hôpital Saint-Louis, Paris, FR. Her expertise lies in chronic lymphoproliferative syndromes, such as Hodgkin and non-Hodgkin lymphoma and chronic lymphocytic leukemia. As the Head of the Hemato-Oncology Department, she contributes to clinical research, including the evaluation of clinical activity in phase II and III trials, as well collaborating with the Center for Clinical Investigations to oversee phase I trials.
Prof. Thieblemont is also a key collaborator with the Université Paris Descartes as part of the NFKB, Differentiation and Cancer group (EA7324), and sits on the Scientific Committee of the European School of Haematology.
Filter by content: